Tiziana Life Sciences partners with Saudi institutions on a trial for multiple sclerosis combination therapy. Partnership for MS trial may advance therapy development and expand market reach without immediate financial or regulatory outcomes.
| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | 1 | 1 | 2 | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2023 | ‡‡‡ |
|
| 2022 | ‡‡‡ |
|
| 2021 | ‡‡‡ |
|
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Cash | 18.12 | 1.18 | 3.72 | 4.01 |
| Receivables | 5.86 | 5.93 | 3.64 | 4.08 |
| Inventory | — | — | — | — |
| Other | 0.20 | — | — | — |
| 24.28 | 7.34 | 7.51 | 8.55 |
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Payables | 6.53 | 6.39 | 7.23 | 10.46 |
| ST’ Debt | 0.15 | — | — | — |
| Other | 0.01 | 0.01 | 0.01 | 0.00 |
| 6.66 | 6.54 | 7.35 | 11.21 |
| 10y | 5y | 3y | |
| Sales | — | — | — |
| Cash Flow | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Earnings | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Book Value | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Year |
|---|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | — | — | — |
—
|
| ’25 | — | (6.82) | — | (12.85) |
(12.85)
|
| ’24 | — | 0.40 | — | (1.53) |
(1.53)
|
| ’23 | — | (11.39) | — | (15.70) |
(15.70)
|
| ’22 | — | (11.91) | — | (19.61) |
(19.61)
|
| ’21 | — | (13.14) | — | (21.76) |
(21.76)
|
| ’20 | — | (6.28) | — | (11.33) |
(11.33)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | — | — | — |
—
|
| ’25 | — | (6.83) | — | (12.87) |
(12.87)
|
| ’24 | — | 0.39 | — | (1.54) |
(1.54)
|
| ’23 | — | (11.39) | — | (15.70) |
(15.70)
|
| ’22 | — | (11.91) | — | (19.61) |
(19.61)
|
| ’21 | — | (13.16) | — | (21.78) |
(21.78)
|
| ’20 | — | (6.29) | — | (11.34) |
(11.34)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | — | — | — |
—
|
| ’25 | — | — | — | — |
(0.16)
|
| ’24 | — | — | — | — |
(0.11)
|
| ’23 | — | — | — | — |
(0.17)
|
| ’22 | — | (0.06) | — | (0.13) |
(0.15)
|
| ’21 | — | (0.17) | — | — |
(0.24)
|
| ’20 | — | (0.04) | — | (0.16) |
(0.16)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 0.53 | 0.50 | 0.41 | 0.63 | — | — | — |
Low Price
|
| — | — | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | 1.38 | 1.39 | 1.74 | 2.60 | — | — | — |
High Price
|
| — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 9 | 9 | 9 | 10 | — | — | — |
Employees
|
| — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue/Emp
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | — | — | — | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (15.40) | (17.24) | (16.75) | (18.43) | — | — | — |
EBT
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | 0.00% | 0.00% | 0.00% | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (15.40) | (17.24) | (16.75) | (18.43) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.05 | 0.10 | 0.12 | 0.23 | — | — | — |
Depreciation
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Revenue/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.15) | (0.17) | (0.11) | (0.16) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Earnings/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.19) | (0.15) | (0.01) | (0.11) | — | — | — |
Cash Flow/Sh
|
| ‡‡‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.19) | (0.15) | (0.01) | (0.11) | — | — | — |
Free CF/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.19 | 0.05 | 0.04 | 0.00 | — | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 102.65 | 104.07 | 106.67 | 118.28 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
PE Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
EV/Sales
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
EV/FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (19.61) | (15.70) | (1.53) | (12.85) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | (0.02) | (0.02) | — | — | — |
Capex
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (19.61) | (15.70) | (1.54) | (12.87) | — | — | — |
FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 17.62 | 0.80 | 0.16 | (2.66) | — | — | — |
Working Cap'
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.44 | — | — | — | — | — | — |
Total Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (17.68) | (1.18) | (3.72) | (4.01) | — | — | — |
Net Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 19.57 | 5.54 | 3.94 | 0.05 | — | — | — |
Sh' Equity
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (40.89%) | (91.52%) | (101.10%) | (161.82%) | — | — | — |
ROA
|
| ‡‡‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | (482.66%) | (258.21%) | (4,656.25%) | 0.00% | — | — | — |
ROIC
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (50.61%) | (140.92%) | (250.49%) | (924.32%) | — | — | — |
ROE
|
Tiziana Life Sciences Ltd (TLSA), a pre-revenue clinical-stage biotech, remains a high-risk speculative play hinging on its lead asset Foralumab, a nasal anti-CD3 antibody for multiple sclerosis and autoimmune diseases. With zero revenue projected through 2027, the company has endured persistent cash burn and equity dilution—shares up 143% since 2016, eroding book value per share by 94% to $0.0365—though recent fiscal discipline shines through, with free cash flow per share improving 93.6% to just -$0.0143 in 2024 and a net cash position of $3.7 million providing a modest runway. Negative ROE (-2.5%) and ROA (-1.01%) underscore inefficient capital use amid stable but tiny headcount of nine employees.
Stock volatility exemplifies biotech lottery dynamics, uncorrelated with fundamentals (Pearson correlation weakly negative at -0.32), driven by pipeline catalysts like 2020’s Phase 2 MS data that spiked shares 486% before an 89% crash. Analyst consensus flashes bold optimism with 326% upside potential from recent levels, tied to ongoing Phase 3 trials and possible 2026-2027 readouts, yet zero insider activity over two years and heavy reliance on external biotech indices (68% price variance) signal caution.
While decelerating losses and trial milestones offer speculative allure, downside risks loom large—60% drawdown on failure, historical dilution drags, and low commercialization odds (15-20%) demand strict position sizing at 1-2% of portfolio. Investors should monitor Q1 2026 updates closely for any inflection amid this precarious balance sheet.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.